Phost’in Therapeutics and the Gianni Bonadonna Foundation Announce Opening of 2 Expansion Cohorts in the PhAST Trial

Montpellier, France – January 2025, 13th

Phost’in Therapeutics (Montpellier, France), a clinical-stage biotechnology company focused on discovery and development of N-glycosylation inhibitors for the treatment of cancer and other serious diseases, today announced a significant achievement in the clinical evaluation of its first-in-class selective N-glycosylation inhibitor, PhOx430. This milestone marks the dosing of the first patients in the Cohort Expansion phase of the PhAST trial, an adaptive Phase I/II study designed to evaluate PhOx430 in patients with advanced solid tumors. The trial is being conducted with the scientific contribution of the Gianni Bonadonna Foundation which collaborated in the conception of the research protocol.